Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

Oklahoma-based Kirrhos Pharmaceuticals tackles fatty liver disease known as NASH

    Home News Oklahoma-based Kirrhos Pharmaceuticals tackles fatty liver disease known as NASH
    NextPrevious

    Oklahoma-based Kirrhos Pharmaceuticals tackles fatty liver disease known as NASH

    By sarah | News | 0 comment | 20 September, 2019 | 0

    By Scott Meacham
    Copyright © 2019, The Oklahoman

    When a looming medical problem exists, people usually hear about it — so much so that even lay people become familiar with the scientific names — angina, arrhythmia, blastoma, lymphoma, hepatitis and the like.

    Cirrhosis, the condition of scarring and permanent damage to the liver, often from alcohol, is another liver condition often in the public eye. Less commonly known beyond the medical profession, however, are the underlying causes of cirrhosis that are not related to hepatitis or alcohol.

    Two of those conditions are nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)—conditions, which are related to too much fat being stored in the liver occurring in people who do not drink.

    In the U.S., NAFLD affects an estimated 80 million people. NASH, an especially aggressive form of NAFLD which results in inflammation, liver damage, liver scarring, cirrhosis, and liver cancer caused by fat building up in the liver, is projected to be the leading cause of liver transplant by 2020.

    There are no silver bullets in tackling the problem of liver disease. It is very complicated and often involves a multi-pronged approach, tackling diabetes, cardiovascular issues, and more simultaneously. There are drug therapies for these, but there is no drug therapy for fatty liver disease.

    Kirrhos Pharmaceuticals, an Oklahoma-based biotechnology firm is developing an oral drug to treat and reverse the effects of fatty liver disease. With a streamlined development plan, the company expects to put the drug in clinical trials in less than 15 months.

    “The beginning stages of fatty liver disease are reversible,” said Dr. Elaine Hamm, Kirrhos Pharmaceuticals Founder and COO. “If you catch it early, you can stop it. But one of the most frightening aspects of NAFLD is that it is silent. A person can have NAFLD without knowing it, until it progresses to an advanced stage. By then, irreversible liver damage is done.”

    Creating awareness, is top of mind for Dr. Hamm and Kirrhos Pharmaceuticals.

    “Fatty liver disease is a big medical problem and is emerging as one of the most common chronic liver diseases.” she said. “Unfortunately, though millions of Americans are at risk for developing this disease, they may not even know it. Patients need to know about NAFLD and NASH and have meaningful conversations with their physicians early about the dangers of this disease, their own risk factors, and about the impact of diet and exercise on preventing liver damage.’

    Beyond creating therapies that reverse disease, it is critically important that early stage biotech startups are “canaries in the coal mine.”

    As these young companies dig into unsolved problems to improve and save lives, they also play a unique and vital role in education and awareness—especially when it comes to conditions like fatty liver disease which can affect so many in such life-threatening ways. (For more information, visit the Ascend BioVentures website)

    Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at i2E_Comments@i2E.org

    Dr. Elaine Hamm, Elaine Hamm, Kirrhos Pharmaceuticals, liver disease, NASH, Scott Meacham

    Related Post

    • There’s no single path to entrepreneurial success

      By sarah | Comments are Closed

      By Scott Meacham There is no single path to entrepreneurial success. U.S. Patent No. 4,371,752 is just one of the more than thirty-three patents issued to Tulsa born and raised inventor and entrepreneur Gordon MatthewsRead more

    • Nautilus inventor created source of wealth and jobs

      By sarah | Comments are Closed

      By Scott Meacham The inventor of the Nautilus exercise machines created a source of wealth and jobs. Arthur A Jones, the inventor of Nautilus exercise machines, grew up in Seminole, OK. His father practiced medicine.Read more

    • Charles Machine Works a case study in entrepreneurship

      By sarah | Comments are Closed

      By Scott Meacham Charles Machine Works is a case study in entrepreneurship and innovation. To succeed in entrepreneurship, solve a problem that lots of businesses have. You can be even more successful, if the businessRead more

    • A real life success story in Ed Roberts and the Altair 8800

      By sarah | Comments are Closed

      By Scott Meacham Oklahoma State University alumni Ed Roberts is a real life success story with the invention of the Altair 8800 personal computer. About a third of i2E’s clients are in software/IT businesses. WeRead more

    • iMCI leads $750,000 investment in OKC-based PrivacyBrain

      By sarah | Comments are Closed

      Back to Newsletter March 17, 2021 Contact: Sarah Seagraves, Senior VP for Marketing sseagraves@i2E.org OKLAHOMA CITY — i2E Management Co., Inc., (iMCI) recently led a $750,000 seed-round investment in Oklahoma City-based PrivacyBrain. PrivacyBrain is aRead more

    Leave a Comment

    Cancel reply

    You must be logged in to post a comment.

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Library
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592
    Click HERE for printable map with directions.
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • #withOklahomaStartups
    • #withOklahomaStartups
    • #withOklahomaStartups- copy
    • 2016 BrewFest
    • 2018 Paulsen Award Application
    • 2019 Business Plan Submittal Form
    • 2019 Intent to Compete
    • 2019 Oral Competition Submittal Form
    • 2019 Paulsen Award Application
    • 2020 Business Plan Submittal Form
    • 2020 Oral Competition Submittal Form
    • 2020 Paulsen Award Application
    • 2021 Official Application Form
    • 2021 Oral Competition Submittal Form
    • 2021 Paulsen Award Application
    • 4DSales
    • About
    • About i2E
    • About Us
    • ACT Tulsa
    • Add Listing
    • Alkami
    • Biolytx
    • BP Endo
    • Clear River Enviro
    • Concept Fund
    • Contact
    • COVID-19 News from i2E
    • COVID19 Resources for Scalable Startups
    • CreditPoint
    • Datebox
    • DermaMedics
    • DEX Pump
    • DigitalSix
    • Directory
    • Directory Dashboard
    • Docvia
    • Driven Analytics
    • e3
    • e3 Goes Virtual
    • e3: #withOklahomaStartups
    • Entrepreneurial Development
    • Entrepreneurial Summit
    • Entrepreneurial Summit Speakers
    • Entrepreneurs-in-Residence
    • Entrepreneurship
    • Events
    • Events
    • Exaptive
    • Exerbotics
    • Expert TA
    • Founder’s Book Nook
    • Home
    • Home
    • i2E Directory
    • i2E Events
    • iMCI
    • iMCI Investment Funds
    • Investments
    • iRecommend
    • Kirrhos
    • Letter from iMCI’s Executive in Residence in a time of great uncertainty
    • Library
    • Lifetone
    • Linear Health Sciences
    • Love’s Cup
      • Forms
      • High Growth
      • Paulsen Awards
      • Small Business
      • Timeline
    • Love’s Cup is Unstoppable
    • Love’s Cup W-9
    • MaxQ
    • Moleculera Labs
    • Monscierge
    • MS Pen Technologies
    • My Account
    • News
    • Newsletter
    • Newsletter Archive
    • OKBio
    • OKBio Directory
    • OMRF Glioblastoma
    • Otologics Pharmaceuticals
    • Past Winners
    • PhotoniCare
    • PolySkope Labs
    • Portfolio
    • Portfolio 3
    • Private Partners Opportunity Fund
    • Progentec Diagnostics
    • Q&A with Kevin Moore
    • Q&A with Michael Basch
    • Quarterly Report
    • Raw Space for Rent
    • Resources
    • Roll to Roll Technologies
    • Selexys Pharmaceuticals
    • Send a Ride
    • Simergent
    • Spiers New Technologies
    • Synercon Technologies
    • Tailwind
    • Ten Nine Technologies
    • Testimonials
    • Tetherex Pharmaceuticals
    • The Greg Main Distinguished Scholar Award
    • THG Energy Solutions
    • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
    • Thoughts Post Shut In
    • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
    • Tulsa GEW
    • Valve Systems International
    • Venture Advisory Services
    • Video
    • Virtuoso
    • Webmail Test Page
    • WeGoLook
    • Well Checked Systems
    • Whiteboard CRM
    i2E